{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:56:43Z","timestamp":1781647003117,"version":"3.54.5"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T00:00:00Z","timestamp":1775174400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018778","name":"Al-Azhar University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018778","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Guillain\u2013Barr\u00e9 syndrome (GBS) is the most common cause of acute flaccid paralysis in children. Intravenous immunoglobulin (IVIG) is considered the standard therapy; however, the potential benefit of adjunctive corticosteroids remains uncertain.This study aimed to explore whether the addition of short-course intravenous methylprednisolone to IVIG may accelerate recovery and alleviate neuropathic pain in pediatric patients with GBS. A prospective, comparative study was conducted at Al-Azhar University Hospitals, enrolling 28 pediatric patients with clinically and electrophysiologically confirmed GBS. Participants were randomized into two equal groups: Group A received IVIG alone (1\u00a0g\/kg\/day for two days), while Group B received IVIG combined with pulse-dose methylprednisolone (30\u00a0mg\/kg\/day for five days). Clinical outcomes including time to initial improvement, unaided ambulation, Hughes Disability Score, neuropathic pain, and adverse events were assessed over a six-month follow-up period. Baseline characteristics were comparable between groups. The combination therapy group demonstrated faster initial improvement (median 3 vs. 4.5 days), earlier independent ambulation (21 vs. 28 days), and modest improvement in Hughes score at three months (median 0 vs. 1,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.016), though clinical significance is limited. Neuropathic pain resolved completely in the steroid group but persisted in 57.1% of the IVIG-only group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002). By six months, nearly all patients achieved complete recovery. Adverse events in the combination group were limited to mild weight gain and increased appetite. Short-course methylprednisolone as an adjunct to IVIG may provide early benefits, particularly in pain resolution, without major safety concerns. These findings are preliminary and hypothesis-generating, requiring confirmation in larger multicenter trials. These findings highlight a feasible and safe strategy that could be particularly valuable in resource-limited healthcare settings, though confirmation in larger multicenter trials is warranted.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-44160-w","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:00:58Z","timestamp":1775127658000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Methylprednisolone as an adjunct to intravenous immunoglobulin in pediatric Guillain\u2013Barr\u00e9 syndrome: a prospective comparative study"],"prefix":"10.1038","volume":"16","author":[{"given":"Abdel-Ghaffar Ismail","family":"Fayed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelsattar Abdullah","family":"Elsayeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ali Saeed","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"44160_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yapd.2023.04.001","author":"MM Langille","year":"2023","unstructured":"Langille, M. M. Guillain\u2013Barr\u00e9 Syndrome in children and adolescents. Pediatr. Clin. North Am. https:\/\/doi.org\/10.1016\/j.yapd.2023.04.001 (2023).","journal-title":"Pediatr. Clin. North Am."},{"key":"44160_CR2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s13312-021-2302-7","volume":"58","author":"S Sen","year":"2021","unstructured":"Sen, S., Kumar, A. & Roy, B. Clinical outcome of Guillain\u2013Barr\u00e9 syndrome in 108 children. Indian Pediatr. 58, 833\u2013835. https:\/\/doi.org\/10.1007\/s13312-021-2302-7 (2021).","journal-title":"Indian Pediatr."},{"issue":"9","key":"44160_CR3","doi-asserted-by":"publisher","first-page":"CD002063","DOI":"10.1002\/14651858.CD002063.pub6","volume":"2014","author":"RAC Hughes","year":"2014","unstructured":"Hughes, R. A. C., Swan, A. V. & van Doorn, P. A. Intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database Syst. Reviews. 2014 (9), CD002063. https:\/\/doi.org\/10.1002\/14651858.CD002063.pub6 (2014).","journal-title":"Cochrane Database Syst. Reviews"},{"key":"44160_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejpn.2020.01.003","volume":"25","author":"R Korinthenberg","year":"2020","unstructured":"Korinthenberg, R. et al. Diagnosis and treatment of Guillain\u2013Barr\u00e9 Syndrome in childhood and adolescence: An evidence- and consensus-based guideline. Eur. J. Pediatr. Neurol. 25, 5\u201316. https:\/\/doi.org\/10.1016\/j.ejpn.2020.01.003 (2020).","journal-title":"Eur. J. Pediatr. Neurol."},{"issue":"8093","key":"44160_CR5","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/s0140-6736(78)92644-2","volume":"2","author":"RA Hughes","year":"1978","unstructured":"Hughes, R. A., Newsom-Davis, J. M., Perkin, G. D. & Pierce, J. M. Controlled trial of prednisolone in acute polyneuropathy. Lancet 2 (8093), 750\u2013753. https:\/\/doi.org\/10.1016\/s0140-6736(78)92644-2 (1978).","journal-title":"Lancet"},{"issue":"10","key":"44160_CR6","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","volume":"7","author":"PA van Doorn","year":"2008","unstructured":"van Doorn, P. A., Ruts, L. & Jacobs, B. C. Clinical features, pathogenesis, and treatment of Guillain\u2013Barr\u00e9 syndrome. Lancet Neurol. 7 (10), 939\u2013950. https:\/\/doi.org\/10.1016\/S1474-4422(08)70215-1 (2008).","journal-title":"Lancet Neurol."},{"key":"44160_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12883-022-02567-8","volume":"22","author":"L Ma","year":"2022","unstructured":"Ma, L. et al. Comparison of the effects of different doses of glucocorticoids on distinct subtypes of Guillain\u2013Barr\u00e9 syndrome in Southern China. BMC Neurol. 22, 46. https:\/\/doi.org\/10.1186\/s12883-022-02567-8 (2022).","journal-title":"BMC Neurol."},{"key":"44160_CR8","doi-asserted-by":"publisher","unstructured":"Priyadarshini, D., Anuhya, V. & Mahapatra, A. Clinico-epidemiological profile and prediction of outcome in children with Guillain\u2013Barr\u00e9 syndrome. Ital. J. Pediatr. 51 https:\/\/doi.org\/10.1186\/s13052-025-02037-0 (2025). Article 179.","DOI":"10.1186\/s13052-025-02037-0"},{"key":"44160_CR9","doi-asserted-by":"publisher","first-page":"e000925","DOI":"10.1136\/bmjno-2024-000925","volume":"6","author":"N Papri","year":"2024","unstructured":"Papri, N. et al. Pain determinants and quality of life in Guillain\u2013Barr\u00e9 syndrome: A prospective cohort study. BMJ Neurol. Open. 6, e000925. https:\/\/doi.org\/10.1136\/bmjno-2024-000925 (2024).","journal-title":"BMJ Neurol. Open."},{"key":"44160_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s12098-025-05737-x","author":"T Chen","year":"2025","unstructured":"Chen, T., Xu, Y. & He, B. Serial serum immunoglobulin G levels and correlation with outcomes in children with Guillain\u2013Barr\u00e9 syndrome: Correspondence-1. Indian J. Pediatr. https:\/\/doi.org\/10.1007\/s12098-025-05737-x (2025).","journal-title":"Indian J. Pediatr."},{"key":"44160_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2147\/PHMT.S401461","volume":"14","author":"MS Shibeshi","year":"2023","unstructured":"Shibeshi, M. S., Mengesha, A. A. & Gari, K. T. Pediatric Guillain\u2013Barr\u00e9 syndrome in a resource-limited setting: Clinical features, diagnostic and management challenges, and hospital outcome. Pediatr. Health Med. Ther. 14, 107\u2013115. https:\/\/doi.org\/10.2147\/PHMT.S401461 (2023).","journal-title":"Pediatr. Health Med. Ther."},{"key":"44160_CR12","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1186\/s12887-024-05298-6","volume":"24","author":"T Ali","year":"2024","unstructured":"Ali, T., Hkima Abou Fakher, F., Alawir, M., Allababidi, A. & Sheikh Hasan, A. Management of severe pediatric Guillain\u2013Barr\u00e9 syndrome in a low-income country: Efficacy and safety of therapeutic plasma exchange in pediatric patients: A retrospective study. BMC Pediatr. 24, 818. https:\/\/doi.org\/10.1186\/s12887-024-05298-6 (2024).","journal-title":"BMC Pediatr."},{"issue":"3","key":"44160_CR13","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s10072-024-07862-5","volume":"46","author":"RM Surve","year":"2025","unstructured":"Surve, R. M. et al. Clinical characteristics and functional outcomes of pediatric Guillain\u2013Barr\u00e9 syndrome admitted to the neuro-intensive care unit: A decade-long retrospective observational study. Neurol. Sci. 46 (3), 1369\u20131377. https:\/\/doi.org\/10.1007\/s10072-024-07862-5 (2025).","journal-title":"Neurol. Sci."},{"issue":"10","key":"44160_CR14","doi-asserted-by":"publisher","first-page":"CD001446","DOI":"10.1002\/14651858.CD001446.pub5","volume":"2016","author":"RAC Hughes","year":"2016","unstructured":"Hughes, R. A. C., Brassington, R., Gunn, A. A. & van Doorn, P. A. Corticosteroids for Guillain\u2013Barr\u00e9 syndrome. Cochrane Database Syst. Reviews. 2016 (10), CD001446. https:\/\/doi.org\/10.1002\/14651858.CD001446.pub5 (2016).","journal-title":"Cochrane Database Syst. Reviews"},{"key":"44160_CR15","doi-asserted-by":"publisher","first-page":"1572949","DOI":"10.3389\/fneur.2025.1572949","volume":"16","author":"KC Gorson","year":"2025","unstructured":"Gorson, K. C. Evolving understanding of Guillain\u2013Barr\u00e9 syndrome pathophysiology and the central role of the classical complement pathway in axonal injury. Front. Neurol. 16, 1572949. https:\/\/doi.org\/10.3389\/fneur.2025.1572949 (2025).","journal-title":"Front. Neurol."},{"key":"44160_CR16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s41983-025-01009-9","volume":"61","author":"K Mohamed","year":"2025","unstructured":"Mohamed, K., Farweez, H., Maged, A. E., Haridy, N. A. & S., & Nerve ultrasound as an adjunct to nerve conduction studies in Guillain\u2013Barr\u00e9 syndrome diagnosis: A prospective Egyptian case\u2013control study. Egypt. J. Neurol. Psychiatry Neurosurg. 61, 78. https:\/\/doi.org\/10.1186\/s41983-025-01009-9 (2025).","journal-title":"Egypt. J. Neurol. Psychiatry Neurosurg."},{"issue":"4","key":"44160_CR17","doi-asserted-by":"publisher","first-page":"R164","DOI":"10.1186\/cc10305","volume":"15","author":"MA El-Bayoumi","year":"2011","unstructured":"El-Bayoumi, M. A. et al. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain\u2013Barr\u00e9 syndrome: A randomized study. Crit. Care. 15 (4), R164. https:\/\/doi.org\/10.1186\/cc10305 (2011).","journal-title":"Crit. Care"},{"issue":"12","key":"44160_CR18","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1007\/s00381-018-3856-0","volume":"34","author":"ZS Karalok","year":"2018","unstructured":"Karalok, Z. S. et al. Guillain\u2013Barr\u00e9 syndrome in children: Subtypes and outcome. Child\u2019s Nerv. Syst. 34 (12), 2291\u20132297. https:\/\/doi.org\/10.1007\/s00381-018-3856-0 (2018).","journal-title":"Child\u2019s Nerv. Syst."},{"key":"44160_CR19","unstructured":"Disclaimer\/Publisher\u2019s Note. The statements, opinions and data contained in all publications are solely those of the individual authors and contributors and not of MDPI and\/or the editor(s). MDPI and\/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44160-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44160-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44160-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:24:35Z","timestamp":1781645075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44160-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44160"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44160-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Statement\n                      : Written informed consent was obtained from all participants or their legal guardians prior to enrollment and initiation of any study-related procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"The authors declare no conflicts of interest, financial or non-financial, related to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"11368"}}